GlassScriptPhysician profile
Rachel S Klein
NPI 1871813709
$2,031.60
in general payments reported to CMS, 2019-2025
25 companies · $373 in 2025
The $373 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $162 · 2020: $79.17 · 2021: $194 · 2022: $322 · 2023: $352 · 2024: $550 · 2025: $373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,275.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $688.58 | 2019-2025 | |
| Abbvie INC. | $591.01 | 2019-2025 | |
| Leo Pharma INC. | $145.21 | 2019-2023 | Adbry |
| Astrazeneca Pharmaceuticals LP | $78.85 | 2022-2023 | Saphnelo |
| Pfizer INC. | $57.53 | 2022-2023 | |
| Galderma Laboratories, L.P. | $55.92 | 2019-2025 | Aklief |
| Sensus Healthcare, INC. | $51.47 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $40.98 | 2022-2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $37.30 | 2025 | |
| Genzyme Corporation | $36.18 | 2021-2024 | |
| Celgene Corporation | $29.57 | 2019 | |
| Kerecis Limited | $29.32 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Glaxosmithkline, LLC. | $27.12 | 2019 | |
| Springworks Therapeutics, INC. | $20.07 | 2025 | Gomekli |
| Botanix Sb INC | $17.83 | 2025 | Sofdra |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $15.33 | 2024 | Daxxify |
| Strata Skin Sciences, INC. | $15.22 | 2024 | Xtrac |
| Bard Peripheral Vascular, INC. | $14.85 | 2025 | |
| Vyne Pharmaceuticals INC. | $14.21 | 2020 | |
| Lnhc, INC | $13.84 | 2025 | Zelsuvmi |
| Amgen INC. | $13.14 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $12.69 | 2019 | |
| Genentech USA, INC. | $12.35 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $11.03 | 2020 | |
| Organon LLC | $2.00 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Klein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.